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Abstract
Background: There is currently very limited information on the nature and pre-
valence of post‐COVID‐19 symptoms after hospital discharge.
Methods: A purposive sample of 100 survivors discharged from a large University
hospital were assessed 4 to 8 weeks after discharge by a multidisciplinary team of
rehabilitation professionals using a specialist telephone screening tool designed to cap-
ture symptoms and impact on daily life. EQ‐5D‐5L telephone version was also completed.
Results: Participants were between 29 and 71 days (mean 48 days) postdischarge
from hospital. Thirty‐two participants required treatment in intensive care unit (ICU
group) and 68 were managed in hospital wards without needing ICU care (ward
group). New illness‐related fatigue was the most common reported symptom by 72%
participants in ICU group and 60.3% in ward group. The next most common
symptoms were breathlessness (65.6% in ICU group and 42.6% in ward group) and
psychological distress (46.9% in ICU group and 23.5% in ward group). There was a
clinically significant drop in EQ5D in 68.8% in ICU group and in 45.6% in ward group.
Conclusions: This is the first study from the United Kingdom reporting on post-
discharge symptoms. We recommend planning rehabilitation services to manage these
symptoms appropriately and maximize the functional return of COVID‐19 survivors.
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1 | BACKGROUND
On 11 March 2020, coronavirus disease 2019 (COVID‐19) was declared
a global pandemic by theWorld Health Organisation (WHO). The United
Kingdom has been one of the worst affected countries with over
286 000 confirmed cases and more than 44 000 confirmed deaths at the
time of writing.1 COVID‐19 is caused by the coronavirus SARS‐CoV‐2
and presents with a wide spectrum of clinical symptoms. Wu and
McGoogan2 reported that 81% of people with COVID‐19 in China
presented with mild symptoms; 14% presented with symptoms of severe
respiratory dysfunction; and 5% developed a critical illness with re-
spiratory failure, septic shock, and multiple organ dysfunction or failure.
The medium and long‐term problems experienced by survivors of
COVID‐19 after discharge from hospital are currently unknown, but
there is some emerging evidence. An Italian study followed‐up 143 in-
dividuals 7 weeks postdischarge and found 53% reporting fatigue, 43%
breathlessness, and 27% joint pain.3 Postdischarge symptoms may also
be predicted from the previous coronavirus outbreaks of severe acute
respiratory syndrome (SARS) in 2002 and Middle East respiratory syn-
drome (MERS) in 2012. A meta‐analysis of 28 follow‐up studies found
that one‐quarter of hospitalized survivors of SARS and MERS had re-
duced lung function and exercise capacity at 6 months postdischarge.4
At 1 year, posttraumatic stress disorder (PTSD), depression and anxiety,
and reduced quality of life were observed. This study suggested that the
impact of COVID‐19 is likely to be similar.
We believe that it is vital to develop rehabilitation services to
address the impact of COVID‐19 in people who survive the infection.
In the United Kingdom, guidance from NHS England on the needs of
COVID‐19 survivors predicts a high burden of physical, neu-
ropsychological, and social need following discharge, drawing largely
from literature on Acute Respiratory Distress Syndrome.5 However,
COVID‐19 is a truly multisystem disease, with common extra‐
respiratory complications affecting the cardiac (arrhythmias and
myocardial injury), renal (acute kidney injury), gastrointestinal, ner-
vous (neuropathy, encephalopathy), endocrine and musculoskeletal
(weakness, pain, and fatigue) systems.6 Specific data concerning the
rehabilitation needs of this group is therefore urgently required.
To inform service development, our multidisciplinary rehabilita-
tion team examined the impact of COVID‐19 on survivors discharged
from hospital. This study reports the first systematic assessment (in
the current literature) of postdischarge symptoms and rehabilitation
needs in COVID‐19 survivors after hospital discharge.
2 | METHODS
2.1 | Setting
This service evaluation study was conducted within Leeds Teaching
Hospitals NHS Trust (LTHT), one of the largest hospital trusts in Europe
with approximately 1800 beds and providing secondary and tertiary
services to a population of 2.5 million people. Patients treated for
COVID‐19 were followed up by telephone by a multidisciplinary team of
physiotherapists, occupational therapists, dietitians, speech and language
therapists, neuropsychologists, and rehabilitation physicians from LTHT
and Leeds Community Healthcare NHS Trust.
2.2 | Participant identification
Participants were identified using a centrally compiled list of all patients
discharged from LTHT following a positive COVID‐19 test. Inclusion
criteria for telephone follow‐up were: patients diagnosed with COVID‐
19 by polymerase chain reaction (PCR) test of a nasopharyngeal sample
during inpatient hospital admission, 4 weeks, or more since discharge
from hospital for the index admission, not currently a hospital inpatient,
and resident within the Leeds Metropolitan District. Exclusion criteria
were if no contact details were available for the patient, under 18 years
of age, or if telephone contact was inappropriate due to dementia,
learning disability, or other cognitive or communication impairment.
We were particularly keen to evaluate the needs of participants
who were treated in the intensive care unit (ICU) at any point during
their hospital admission. Participants who received treatment on the ICU
were expected to present as a distinct group with more severe needs,
therefore, as many as possible of this group were included in follow‐up.
Participants who had received ward‐based care were then selected
randomly from the list and we continued to recruit participants until a
total of 100 participants had been successfully followed up. Our results
are presented with two groups disaggregated participants who received
ward‐level care only (who will be referred to as “ward group”) and
participants who received ICU treatment (“ICU group”).
2.3 | Development of the telephone screening tool
A COVID‐19 rehabilitation telephone screening tool was developed by
the multidisciplinary team using an iterative peer review process. Do-
mains captured in the tool were breathlessness, fatigue, swallowing,
nutrition, voice quality, laryngeal sensitivity, communication, PTSD dis-
order, continence, cognition, perceived health status, vocation, and fa-
mily/carers’ views. The impact of each domain on the participant
functioning was graded using a Likert scale to assess the impact pre‐ and
post‐COVID‐19 disease. Additionally, the domains of mobility, personal
care, usual activities, pain and anxiety/depression were addressed using
the EQ‐5D‐5L Version for Interviewer Administration.7 A version of the
telephone screening tool has been mapped toWHO ICF Framework and
been shown to incorporate all domains.8,9
2.4 | Telephone follow‐up of patients postdischarge
Demographic data and admission details of the 100 identified partici-
pants were extracted from electronic patient records using a pre-
determined pro forma. Members of the COVID‐19 rehabilitation
multidisciplinary team (MDT) conducted telephone follow‐up using the
screening tool. Patients were called at various times throughout the day
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to allow for increased chances of success with calls. Informed verbal
consent was taken to proceed with the telephone consultation. Patients
were directed to self‐management resources, given specialist advice, and
referred to relevant rehabilitation services as required. The completed
Microsoft Word telephone screening tool was uploaded to the patients’
electronic records and imported to a Microsoft Excel spreadsheet.
Patient information was stored securely and accessed via NHS
computers. Only the relevant and necessary patient data was shared
with individual clinicians involved in conducting the telephone sur-
veys, via secure nhs.net email systems.
2.5 | Analysis
Data analysis was carried out using Microsoft Excel with descriptive
statistics. Mean (and SD) is used to present average values for normal
data and median (and interquartile range) used to present nonnormal
data. Prevalence is reported as number of and percentage of patients
reporting the symptom within the group (ICU or ward).
3 | RESULTS
One hundred and ninety‐one potential participants were identified from
the central list, 33 were deemed inappropriate for telephone follow‐up
due to dementia, cognitive impairment or receiving palliative care; 56 had
wrong numbers or did not answer repeated phone calls; and 2 declined to
participate. One hundred participants completed the telephone screen
over a 4‐week period fromMay to June 2020. Participants were between
29 and 71 days postdischarge (mean 48 days and SD 10.3 days).
Demographics and comorbidities (pre‐COVID‐19) of the cohort
are displayed in Table 1. Table 2 provides details of the index ad-
mission. Patients predominantly had single‐organ (respiratory) dys-
function requiring oxygen or noninvasive ventilation and only one
patient in this cohort was intubated. This low rate of intubation re-
flects the timing of this study in relation to the pandemic wave seen
in our hospitals. As such, those who required intubation had largely
not been discharged for long enough to be included in this study.
The prevalence of reported problems detected on telephone
screening after hospital discharge are reported in Table 3 and Figure 1
3.1 | Fatigue
Extremely high levels of fatigue were reported. The severity of the
impact of this fatigue was high, with a mean rating of 4.8 out of 10
across both groups. Moderate or severe fatigue (rated 4 + /10) was
reported more frequently by female patients than male patients in
both groups. Overall, 61% of those with moderate or severe fatigue
were female and 54.3% of all female patients reported moderate or
severe fatigue, compared to 29.6% of male patients. There was no
marked difference in ethnicity or body mass index (BMI) between
those with moderate to severe fatigue and those without. In the ward
TABLE 1 Demographics and pre‐COVID‐19 comorbidities of







Total no. 68 32
Age, median (range), y 70.5 (20‐93) 58.5 (34‐84)
Sex
Female 33 (48.5) 13 (40.6)
Male 35 (51.5) 19 (59.4)
Ethnicity
White 54 (79.4) 19 (59.4)
Mixed 1 (1.5) 0
Asian or Asian British 2 (2.9) 8 (25)
Black or Black British 5 (7.4) 3 (9.4)
Other Ethnic groups 0 0
Unknown 6 (8.8) 2 (6.3)
Occupation
Keyworker 16 (23.5) 14 (20.6)
Works in a health care setting 4 (5.9) 11 (16.2)
Comorbidities
Body mass index
Underweight 2 (2.9) 1 (3.3)
Healthy weight 18 (26.5) 7 (23.3)
Overweight 25 (36.8) 10 (33.3)
Obese 12 (17.6) 12 (40.0)
Unknown 11 (16.2) 0
Cancer
Active 7 (10.3) 0
Active or previous 16 (23.5) 5 (15.6)
Cardiovascular disease
Heart failure 5 (7.4) 0
Hyperlipidemia 2 (2.9) 2 (6.3)
Hypertension 27 (39.7) 14 (43.8)
Ischemic heart disease 9 (13.2) 1 (3.1)
Tachyarrhythmias 9 (13.2) 2 (6.3)
Valvular heart disease 2 (2.9) 1 (3.1)
Venous thromboembolism 4 (5.9) 1 (3.1)
Chronic respiratory disease
Asthma 9 (13.2) 4 (12.5)
Chronic obstructive
pulmonary disease
6 (8.8) 2 (6.3)
Obstructive sleep apnea 4 (5.9) 3 (9.4)
Other 3 (4.4) 0
Chronic kidney disease 11 (16.2) 4 (12.5)
Other urological disease 9 (13.2) 4 (12.5)
Endocrine
Type 1 diabetes 1 (1.5) 0
Type 2 diabetes 19 (27.9) 9 (28.1)
Prediabetic 5 (7.4) 1 (3.1)
(Continues)
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group, those with moderate to severe fatigue appeared to be younger
than those without (mean of 63 years vs 67 years). There was no age
difference in the ICU group. In both groups, patients with moderate
or severe fatigue also had markedly higher levels of PTSD symptoms
(43.9% vs 18.6%) cognitive problems (41.4% vs 18.6%) and breath-
lessness (65.9% vs 39.0%) than those without moderate to severe
fatigue.
3.1.1 | Breathlessness
New or worsened breathlessness (when compared with pre‐COVID
illness) was a significant symptom even several weeks postdischarge,
affecting over two‐fifths of ward patients and two‐thirds of ICU
patients. Moderate or severe breathlessness was more often re-
ported by females than males in the ICU group (53.8% compared
with 21.1%) but the proportions were similar in the ward group
(24.2% and 20.0%). Among all patients for whom ethnicity was
known, 8/19 (42.1%) of Black Asian and Minority Ethnic (BAME)
participants reported moderate or severe breathlessness, compared
with 18/72 (25.0%) of white patients. In the ICU group, 54.5% of
those with moderate or severe breathlessness were obese, compared
with 28.6% of those who were not so breathless. Among all those for
whom BMI was known, 9/24 (37.5%) of obese people had moderate
or severe breathlessness, compared with 17/63 (27.0%) of those with
a BMI of less than 30. Of the ICU patients aged 60 and above, 92.3%
reported some degree of worsened breathlessness, compared with
47.4% of those aged below 60, whereas in the ward patients the
proportion of patients reporting breathlessness was more similar
across age groups, the highest group being patients aged 50 to 59 at
58.3%. One‐fifth of the participants in each group had some degree
of pre‐existing breathlessness before developing COVID‐19 illness.
Of those who reported post‐COVID breathlessness, 60% of ward
participants and 66% of ICU participants had pre‐existing respiratory
conditions.
3.1.2 | Neuropsychological
PTSD symptoms were reported by a much higher proportion of fe-
males (10/13; 76.9%) than males (5/19; 38.5%) in the ICU, whereas in
the ward group these proportions were similar (22.9% of males and
24.2% of females). In both groups, those reporting PTSD symptoms
were younger. The median age of all participants with these symp-
toms was 59 years, compared with 68 years in those without PTSD
symptoms. PTSD symptom reporting co‐occurred with obesity in the
ICU group, but not in the ward group. Eighty percent of the ICU
group reporting PTSD symptoms (12/15 people) were obese. 85.7%







Thyroid disease 2 (2.9) 3 (9.4)
Other 3 (4.4) 0
Gastrointestinal disease 20 (29.4) 5 (15.6)
Gynecological disease 3 (4.4) 0
Hematological disease (excluding
malignancy)
4 (5.9) 6 (18.8)
Immunosuppressed 9 (13.2) 6 (18.8)
Infectious disease 3 (4.4) 3 (9.4)
Mental health condition 14 (20.6) 5 (15.6)
Musculoskeletal disease and
rheumatology
Osteoarthritis 11 (16.2) 2 (6.3)
Rheumatological disease 6 (8.8) 8 (25.0)
Other musculoskeletal disease 12 (17.6) 5 (15.6)
Neurological disease 8 (11.8) 4 (12.5)
Total with ≥3 significant
comorbidities
48 (70.6) 18 (56.3)




Median hospital LoS in days 6.5 12
Interquartile range hospital
LoS in days
10 (4‐14) 6 (10‐16)
Median ICU LoS in days 4
Interquartile range ICU LoS
in days
3.15 (2.6‐5.75)
N % N %
Level of respiratory support
O2 46 67.7 32 100
CPAP/NIV 2 2.9 28 87.5
Endotracheal I + V 0 0 1 3.1
Tracheostomy 0 0 0 0
Renal replacement therapy 2 2.9 1 3.1
Artificial feeding
NG/NJ 2 2.9 4 12.5
PN 0 0 1 3.1
Seen by physiotherapy 40 58.8 31 96.9
Seen by OT 20 29.4 9 38.1
Seen by dietitian 11 16.2 14 43.8
Seen by SLT 4 5.9 2 6.3
Abbreviations: CPAP, continuous positive airway pressure; I + V, intubation
and ventilation; ICU, intensive care unit; LoS, length of stay; NG, nasogastric;
NIV, noninvasive ventilation; NJ, nasojejunal; OT, occupational therapy; PN,
parenteral nutrition; SLT, speech and language therapy.
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TABLE 3 Prevalence of reported
problems after COVID‐19 in patients
discharged from hospital Domain
Ward patients (68) ICU patients (32)
Number % Number %
Fatigue
Any new fatigue 41 60.3 23 72.0
Mild (0‐3) 17 25.0 6 18.8
Moderate (4‐6) 14 20.6 13 40.6
Severe (7‐10) 10 14.7 4 12.5
Breathlessness
Any new or worsened breathlessnessa 29 42.6 21 65.6
Mild (increased by 1‐3/10) 14 20.6 10 31.3
Moderate (increased by 4‐6/10) 10 14.7 7 21.9
Severe (increased by 7‐10/10) 5 7.4 4 12.5
Increased at rest 13 19.1 9 28.1
Increased on dressing 18 (/66)b 27.3 10 31.3
Increased on stairs 24 (/57)b 42.1 21 65.6
Neuropsychological
Any PTSD symptoms related to illness 16 23.5 15 46.9
Mild symptoms 12 17.6 9 28.1
Moderate symptoms 4 5.9 4 12.5
Severe symptoms 0 0.0 2 6.3
Thoughts of self‐harm 1 1.5 1 3.1
New or worsened concentration problem 11 16.2 11 34.4
New or worsened short‐term memory problem 12 17.6 6 18.8
Speech and swallow
Swallow problem 4 5.9 4 12.5
Laryngeal sensitivity 9 11.8 8 25.0
Voice change 12 17.6 8 25.0
Communication difficulty 4 5.9 2 6.3
SLT referral criteria met (impact rating of 1 or
more in any SLT domain)
14 20.6 9 28.1
Nutrition
Concern about weight/nutrition 10 14.7 2 6.3
Appetite problem severity 2 or more 6 8.8 2 6.3
Dietetics referral criteria met (either of the
above criteria)
12 17.6 4 12.5
Continence
New bowel control problem 2 2.9 1 3.1
New bladder control problem 6 8.8 4 12.5
EQ‐5D‐5L
Mean EQ‐5D‐5L index value on day of screen 0.724 0.693
Mean change −0.061 −0.155
Decreased by at least 0.05 (MCIDc) 31 45.6 22 68.8
Worsened mobility 21 30.9 16 50
Worsened self‐care 12 17.6 4 12.5
Worsened usual activities 25 36.8 19 29.4
Worsened pain/discomfort 10 14.7 9 28.1
Worsened anxiety/depression 11 16.2 12 37.5
Perceived health (self‐rated 0‐100 scale)
Mean change −5.8 −12.53
Decrease by more than 7 points (MCIDc) 22 32.4 17 53.1
Health service contact
Represented to hospital 8 11.8 4 12.5
Used other health services 42 61.8 21 65.6
(Continues)
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those with a BMI of less than 30, in the ICU group. Overall the rates
of PTSD symptoms reported by BAME individuals were similar to
white participants (35.0% and 29.2%). Of the 35 participants overall
reporting anxiety and depression post‐COVID‐19, 74% had no pre-
viously diagnosed mental health condition.
3.1.3 | Speech, swallow, and nutrition
Symptoms relating to communication, voice, swallow, and laryngeal
sensitivity (including persistent cough) were more common in the
ICU group than the ward group. There was no clear difference in age,
gender or ethnicity between those who reported these symptoms
and those who did not. In the ICU group, 5/12 (41.7%) of obese
people reported these problems, compared with 3/18 (16.7%) of
people with a BMI under 30. Recorded weight change during hospital
admission was available for 36 of the ward group and 21 of the ICU
group. Both showed an average weight loss of 1 kg with no marked
difference between the groups.
3.1.4 | Daily activities and health‐related quality of
life (QOL)
Of the 22 ICU participants experiencing new problems in mobility,
self‐care or usual activities, 17 had new or worsened breathlessness
and 19 had new fatigue. There was no difference in age, ethnicity,
BMI, or gender between those who reported problems with mobility,
TABLE 3 (Continued)
Domain
Ward patients (68) ICU patients (32)
Number % Number %
Vocation change since COVID‐19 illness n = 20d n = 20d
Returned to same level of employment 14 70.0 2 10.0
Previously full time, now part‐time 0 0.0 2 10.0
Off sick 3 15.0 12 60.0
Furloughed 2 10.0 4 20.0
Newly retired 1 5.0 0 0.0
aWhen compared with pre‐COVID‐19.
bDenominator differs as not all patients performed these activities.
cMinimal clinically important difference as validated in respiratory disease.10
dTwenty patients from each group were previously in full or part‐time employment before their
hospital admission.
F IGURE 1 Prevalence of persistent symptoms in the intensive care unit and ward groups
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self‐care, or usual activities, and those who did not. Of the 30 ward
participants experiencing new problems in mobility, self‐care or usual
activities, 21 had new or worsened breathlessness and 26 had new
fatigue. There was no difference in age, ethnicity, or BMI between
the participants with these problems and those without, but 67% of
those with these problems were female. Sixty‐one percent of female
ward patients reported these problems, compared with 29% of male
ward participants. The change in scores in the five domains of EQ‐5D
5 L due to COVID‐19 is shown in Figures 2 and 3.
4 | DISCUSSION
This is the first UK study of its kind on the postdischarge medium‐
term impact of COVID‐19 infection on the health status of survivors.
New illness‐related fatigue was the most common reported symptom
by 72% participants in the ICU group and 60.3% participants in the
ward group. The next common symptoms were breathlessness
(65.6% in ICU group and 42.6% in ward group) and psychological
distress (46.9% in ICU group and 23.5% in ward group). There was a
clinically significant drop in EQ5D in 68.8% of participants in the ICU
group and in 45.6% of participants in the ward group. Sixty percent of
the ICU group and 15% of the ward group remained off‐sick from
work at the point of follow‐up.
This duration of symptom persistence appears to be greater than
that seen in community‐acquired bacterial pneumonia. A longitudinal
study of time to symptom recovery in patients with community‐
acquired pneumonia hospitalized for an identical median length of stay
to our ward group (6 days) found that on average patients had re-
covered 97% of their symptoms by 10 days.11 A further longitudinal
study including 201 patients hospitalized with community‐acquired
pneumonia showed that breathlessness settled after an average of 14
days from symptom onset, and fatigue after 20 days.12 The findings in
this study are similar to the Italian COVID‐19 Post‐Acute Care Study.3
Fatigue, breathlessness, joint pain, and reduced QoL were the most
common problems observed in that prospective study involving 143
individuals. Our study in addition measures the severity of symptoms
and rehabilitation needs of the individuals. We have also investigated
the difference between ward and ICU‐managed individuals.
Current literature on previous coronavirus outbreaks also sug-
gests similar postdischarge symptoms. A systematic review and
meta‐analysis of the short‐ and long‐term clinical outcomes after
SARS and MERS identified respiratory compromise, reduced exercise
tolerance, PTSD, and reduced QoL as key issues in survivors, which
can persist up to 12 months after hospital discharge.4 However, our
results contrast with an early report of COVID‐19 postdischarge
symptoms, which emerged from China.13 A prospective cohort study
of 131 COVID‐19 patients who had been discharged from hospital in
Wuhan found that by 3 to 4 weeks postdischarge 86% of patients
were symptom‐free, only 1.5% had shortness of breath and 0% had
fatigue. This study had a younger population (median age 49) with
less comorbidity than that presented in our study; however, the
magnitude of the differences seen between these findings suggest
additional factors. The fact that this study was oriented around de-
tecting ongoing transmissibility, and patients were also questioned
on their quarantine status and contacts raises the possibility of
underreporting.
Fatigue is a multidimensional health problem, which overlaps
with breathlessness, cognitive dysfunction, and psychological distress
as demonstrated in this study (those with moderate or severe fatigue
F IGURE 2 EQ‐5D 5 L scores in the ward
group pre‐ and post‐COVID‐19 (each domain
of EQ‐5D 5 L is scored on a 5‐point scale: 1, no
problem; 2, slight problem; 3, moderate
problem; 4, severe problem; and 5, unable
to do)
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had higher incidence of these symptoms). The prevalence of fatigue is
in keeping with previous epidemics of SARS, H1N1, and Ebola, in
which a large proportion of fatigued patients have been found to
qualify for a diagnosis of Myalgia Encephalomyelitis/Chronic Fatigue
Syndrome (ME/CFS).14 More than half of a sample of patients re-
covering from SARS experienced fatigue throughout their recovery
64% reported fatigue at 3 months, 54% at 6 months, and 60% at 12
months.15
Breathlessness secondary to acute respiratory distress syndrome
(ARDS) and lung parenchymal infiltration disease is an anticipated
symptom that can persist long‐term after discharge. Our study has
demonstrated that those needing ICU admission and respiratory
support, premorbid lung problems, higher age, higher BMI, and
BAME ethnicity are more likely to experience breathlessness post-
discharge. The prevalence is comparable to those reported in the
meta‐analysis study of 11% to 45% of survivors having breath-
lessness even up to 12 months.4 This is also in keeping with com-
puted tomography findings of pulmonary fibrosis that has been
reported to persist up to 7 years after discharge.16
This study found levels of PTSD symptomology to be twice as
high in ICU patients compared to ward patients. This prevalence is in
keeping with the meta‐analysis study that found that a third of sur-
vivors of previous coronavirus epidemics having psychological con-
ditions such as PTSD, depression, and anxiety beyond 6 months of
discharge.4 PTSD symptoms are a well‐recognized component
of post‐ICU syndrome caused by a variety of factors including fear of
dying, invasive treatment, pain, delirium, inability to communicate,
weakness, immobility, and sensory problems and sleep deprivation.17
Post‐illness cough and voice changes were higher in the ICU
group and are in keeping with a recent report describing the care
needs of those affected by Covid‐19, which highlights that patients
with a diagnosis of ARDS often experience airway inflammation,
epithelial damage, and heightened cough reflex sensitivity.18 The
reasons for loss of appetite in COVID‐19 patients are purported to
include the gastrointestinal problems, including diarrhea, vomiting,
and abdominal pain, which are commonly reported symptoms in
COVID‐19 patients.19
Exercise tolerance problems or reduction in daily activities
ability is also multifactorial similar to fatigue. There is overlap with
symptoms of breathlessness, cognition, and psychological distress as
seen in this study. Whether there are cardiac abnormalities con-
tributing to exercise intolerance remains to be explored in future
research. A systematic review of outcomes from previous cor-
onavirus epidemics highlighted that 41% of patients had a reduced
aerobic capacity at 3 months postillness.4 ICU acquired weakness in
patients with acute lung injury has been found to persist in 14% of
patients at 12 months.20 This is likely to contribute to the reduction
in daily activities ability seen in this cohort of COVID‐19 patients.
As the EQ5D measure is a reflection of mobility, self‐care, usual
activities, pain/discomfort, and psychological symptoms, the clinically
significant decrease seen in this cohort reflects the impact of the
illness on quality of life and health burden to the economy. The
previous outbreaks of SARS and MERS used SF‐36 to measure
health‐related QOL and showed a significantly low quality of life at 1
year, lower than the quality of life of those with chronic conditions
(using normative data).4 Given the high prevalence of breathlessness,
fatigue, and psychological symptoms, it is not a surprise that there is
a significant impact on fitness for work. One study found that two‐
thirds of previously employed ICU‐survivors are jobless up to 3, 6,
12, and 60 months following hospital discharge.21
F IGURE 3 EQ‐5D 5 L scores in the
intensive care unit group pre‐ and post‐
COVID‐19 (each domain of EQ‐5D 5 L is
scored on a 5‐point scale: 1, no problem; 2,
slight problem; 3, moderate problem; 4, severe
problem; and 5, unable to do)
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Patients admitted to ICU in this study had a greater prevalence
of symptoms in almost all reported symptom domains, despite being
a younger and less comorbid group. This is in keeping with the well‐
characterized post‐intensive care syndrome.22 Studies of previous
coronavirus epidemics have reached contrasting conclusions on
whether long‐term pulmonary dysfunction is more common in ICU
patients than ward patients.23,24 Further reporting of outcomes in
ICU COVID‐19 survivors is needed as these impairments are likely to
result in a substantial burden in terms of reduced physical function
and quality of life.
This study has some limitations. The MDT made use of telephone
calls as a method of contact, which allowed for data collection during
a restrictive lockdown period; however, this created limitations on
being able to contact certain participants, such as those with de-
mentia, learning difficulties, non‐English speakers. Selected partici-
pants were those who had been diagnosed with a positive PCR swab
result of COVID‐19 while as an inpatient within LTHT; however,
patients who had a negative swab result but who were likely to have
COVID‐19 based on clinicoradiological criteria were not included in
this study. This study does not include COVID‐19 survivors who
were not hospitalized. It is likely that non‐hospitalized COVID‐19
survivors will have different rehabilitation needs to those who were
hospitalized and this merits further investigation.
The presence of comorbidity in some of those interviewed may
have impacted on symptoms reported. Due to the necessity of
gathering this information in real‐time as the pandemic unfolded,
patients with a longer inpatient admission time, such as those in-
tubated in ICU are underrepresented in our cohort as they remained
in hospital at the time of this follow‐up. Telephone contact was made
as a single point of follow‐up. This method of data collection does not
capture how problems evolve over time, and further follow up at 3, 6,
or 12 months would aid further understanding of the progression of
symptoms post‐COVID‐19.
To conclude, COVID‐19 is a new illness, with symptoms post-
discharge yet to be researched. This study is first of its kind to
capture these symptoms in a cohort of patients discharged from a
large tertiary teaching hospital. New illness‐related fatigue, breath-
lessness, and psychological distress were commonly reported with
greater prevalence in those needing ICU care when compared with
those managed in wards without needing ICU treatment. There was a
clinically significant drop in quality of life in many participants. Re-
habilitation care for COVID‐19 survivors must, therefore, be need‐
focused, delivered by specialist MDT and planned for the longer term
to meet the needs of these individuals.
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